Editas Medicine, Inc. (EDIT) Balance Sheet

The trajectory is one of rapid contraction, with equity collapsing from $294.4M to $105.3M over the same period, indicating that operational losses are consuming the company's capital base. This trend suggests the business model is not yet generating sufficient returns to stabilize the balance sheet, placing increasing pressure on future financing options.

The strong current ratio is almost entirely a function of the large cash balance relative to liabilities, not operational strength. Given the consistent free cash flow deficits, the cash pile represents a finite runway rather than a strategic asset, and its depletion will directly impact the company's ability to fund its R&D pipeline without dilutive actions.

The extreme fluctuation in leverage, with total debt jumping to $72.0M in 2026Q1 before falling to $15.5M, implies the company may have utilized a convertible note or similar instrument to manage a near-term cash shortfall. This pattern indicates that while headline leverage is currently low, the company's access to capital markets is being actively tested.

The equity base is being hollowed out by the company's inability to generate net income, with the retained earnings deficit growing each quarter. This erosion reduces the book value cushion for creditors and increases the likelihood that future capital raises will be highly dilutive to existing shareholders.

The shrinking PPE balance, combined with the absence of goodwill, indicates an asset-light model focused on intellectual property and cash reserves. However, the rapid decline in total assets is not a sign of efficiency but rather a reflection of capital consumption, leaving the company with fewer tangible assets to leverage for financing.